Neuronetics Q4 Earnings Call Highlights
View original at finance.yahoo.comNeuronetics Q4 Earnings Call Highlights Neuronetics logo Key Points Board appointed Dan Reuvers as CEO effective March 23, as Neuronetics transitions leadership while continuing its strategy to operate a vertically integrated mental-health company combining NeuroStar technology and Greenbrook clinics…
Lo que extrajimos de esta fuente
The claims Via News extracted from this document. We point to the source; we don't replace it.
The company shipped 49 systems in the quarter with average selling price above its target for a fourth consecutive quarter
60% confidenceTotal treatment volume across Spravato and TMS rose 18% year-over-year in the fourth quarter
60% confidenceThe Greenbrook network is positioned to offer REMS-compliant therapies and expects only limited incremental investment to support COMP360 if approved, given alignment with existing Spravato operations
60% confidenceClinic revenue was $23.5 million, representing 37% adjusted pro forma growth, driven by increased treatments across both NeuroStar TMS and Spravato
60% confidenceNeuroStar revenue (systems plus treatment sessions) was $18.3 million, representing 9% growth year-over-year on a pro forma basis
60% confidenceOn an adjusted pro forma basis, revenue increased 23% versus the prior year
60% confidenceThe company shipped 49 systems in the quarter, with average selling price above its target for a fourth consecutive quarter
60% confidenceCash provided by operations in the fourth quarter was positive $0.9 million. Operating cash burn improved sequentially each quarter during 2025, from negative $17 million in the first quarter to positive $0.9 million in the fourth quarter
60% confidenceCOMP360 would be administered in supervised doses within a clinic setting, without a daily or recurring protocol, and would be administered under a REMS protocol similar to Spravato
60% confidenceTRICARE West expanded coverage for TMS therapy to include adolescents age 15 and older diagnosed with depression, effective across 26 states
60% confidenceCompass has completed two phase 3 studies showing highly statistically significant and clinically meaningful results, including durable improvement through at least 26 weeks after one or two doses, and plans to submit an NDA with potential for FDA decision by year-end
60% confidenceThe clinic business is expected to grow in the double digits to mid-teens in 2026, while the NeuroStar business is expected to grow in the low to mid-single digits
60% confidenceCOMP360 would be administered in supervised doses within a clinic setting, without a daily or recurring protocol, and would be administered under a REMS protocol similar to Spravato
60% confidenceCompass Pathways has completed two phase 3 studies showing highly statistically significant and clinically meaningful results, including durable improvement through at least 26 weeks after one or two doses
60% confidenceOperating cash burn improved sequentially each quarter during 2025, from negative $17 million in the first quarter to positive $0.9 million in the fourth quarter
60% confidenceCash provided by operations in the fourth quarter was positive $0.9 million
60% confidenceCompass has about seven strategic collaborations for commercial readiness and Greenbrook is one of them
60% confidenceSince inception, the BMP program has connected more than 66,000 interested patients with BMP providers
60% confidenceThe combined company delivered strong fourth quarter results and reached a key milestone of positive operating cash flow in the period
60% confidenceThe company's strategy following the Greenbrook acquisition was to build a vertically integrated mental health company combining technology, clinical infrastructure, and scale to expand patient access to treatment
60% confidenceFor 2026, total revenue guidance of $160 million to $166 million implies greater than 9% growth versus 2025, with clinic business expected to grow in the double digits to mid-teens and NeuroStar business expected to grow in the low to mid-single digits
60% confidenceSpravato rollout is nearly complete with 84 clinics providing the treatment
60% confidenceCOMP360 would be administered in supervised doses within a clinic setting, without a daily or recurring protocol, and would be administered under a REMS protocol similar to Spravato
60% confidenceFourth-quarter total revenue was $41.8 million, up 86% year-over-year, primarily due to the inclusion of Greenbrook operations
60% confidenceCOMP360 would be administered in supervised doses within a clinic setting, without a daily or recurring protocol, and would be administered under a REMS protocol similar to Spravato
60% confidenceFourth-quarter total revenue was $41.8 million, up 86% year-over-year, primarily due to the inclusion of Greenbrook operations
60% confidenceOn an adjusted pro forma basis, revenue increased 23% versus the prior year
60% confidenceFull-year clinic revenue grew 28% on an adjusted pro forma basis, supported by increased field engagement and a growing network of referring providers
60% confidenceCompass plans to submit an NDA with the potential for an FDA decision by year-end
60% confidenceGross margin was 52% in the fourth quarter, the company's highest quarterly margin of the year, citing clinic efficiency efforts and favorable product mix
60% confidence